RASA2 and cancer: Preclinical models of T-cell receptor and CAR-T therapies confirmed that RASA2-knockout CAR-T cells prolonged survival in mice xenografted with liquid or solid tumors, highlighting RASA2 as a promising target to enhance persistence and effector function in T-cell therapies for cancer treatment (Carnevale et al.2022).